Prucalopride  	Prucalopride  	 NNP	B-NP
for  	for  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
women  	women  	 NNS	O
with  	with  	 IN	O
chronic  	chronic  	 JJ	B-NP
constipation  	constipation  	 NN	I-NP
in  	in  	 IN	O
whom  	whom  	 WP	O
standard  	standard  	 JJ	O
laxative  	laxative  	 NN	O
regimens  	regimens  	 NNS	O
have  	have  	 VBP	O
failed  	failed  	 VBN	O
to  	to  	 TO	O
provide  	provide  	 VB	O
adequate  	adequate  	 JJ	O
relief  	relief  	 NN	O
This  	This  	 DT	O
paper  	paper  	 NN	O
presents  	presents  	 VBZ	O
a  	a  	 DT	O
summary  	summary  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
evidence  	evidence  	 NN	B-NP
review  	review  	 NN	I-NP
group  	group  	 NN	I-NP
( 	( 	 -LRB-	O
ERG 	ERG 	 NNP	O
)  	)  	 -RRB-	O
report  	report  	 NN	O
into  	into  	 IN	O
the  	the  	 DT	O
clinical  	clinical  	 JJ	B-NP
effectiveness  	effectiveness  	 NN	I-NP
and  	and  	 CC	O
cost-effectiveness  	cost-effectiveness  	 JJ	B-NP
of  	of  	 IN	I-NP
prucalopride  	prucalopride  	 NN	I-NP
for  	for  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
women  	women  	 NNS	O
with  	with  	 IN	O
chronic  	chronic  	 JJ	B-NP
constipation  	constipation  	 NN	I-NP
in  	in  	 IN	O
whom  	whom  	 WP	O
standard  	standard  	 JJ	O
laxative  	laxative  	 NN	O
regimens  	regimens  	 NNS	O
have  	have  	 VBP	O
failed  	failed  	 VBN	O
to  	to  	 TO	O
provide  	provide  	 VB	O
adequate  	adequate  	 JJ	O
relief 	relief 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
ERG  	ERG  	 NNP	O
report  	report  	 NN	O
is  	is  	 VBZ	O
based  	based  	 VBN	O
on  	on  	 IN	O
the  	the  	 DT	O
manufacturer 	manufacturer 	 NN	O
's  	's  	 POS	O
submission  	submission  	 NN	O
( 	( 	 -LRB-	O
MS 	MS 	 NNP	B-NP
)  	)  	 -RRB-	O
to  	to  	 TO	O
the  	the  	 DT	O
National  	National  	 NNP	O
Institute  	Institute  	 NNP	O
for  	for  	 IN	O
Health  	Health  	 NNP	O
and  	and  	 CC	O
Clinical  	Clinical  	 NNP	B-NP
Excellence  	Excellence  	 NNP	I-NP
as  	as  	 IN	O
part  	part  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
single  	single  	 JJ	O
technology  	technology  	 NN	B-NP
appraisal  	appraisal  	 NN	I-NP
process 	process 	 NN	I-NP
.  	.  	 .	O
In  	In  	 IN	O
the  	the  	 DT	O
submission 	submission 	 NN	O
,  	,  	 ,	O
quality-of-life  	quality-of-life  	 JJ	B-NP
data  	data  	 NNS	I-NP
[ 	[ 	 -LRB-	O
Patient  	Patient  	 NNP	B-NP
Assessment  	Assessment  	 NNP	I-NP
of  	of  	 IN	I-NP
Constipation  	Constipation  	 NNP	I-NP
Quality  	Quality  	 NNP	I-NP
of  	of  	 IN	I-NP
Life  	Life  	 NNP	I-NP
( 	( 	 -LRB-	O
PAC-QOL 	PAC-QOL 	 NNP	B-NP
)  	)  	 -RRB-	O
and  	and  	 CC	O
Patient  	Patient  	 NNP	B-NP
Assessment  	Assessment  	 NNP	I-NP
of  	of  	 IN	I-NP
Constipation  	Constipation  	 NNP	I-NP
Symptoms  	Symptoms  	 NNP	I-NP
( 	( 	 -LRB-	O
PAC-SYM 	PAC-SYM 	 NNP	B-NP
)  	)  	 -RRB-	O
questionnaires 	questionnaires 	 NN	O
]  	]  	 -RRB-	O
from  	from  	 IN	O
trials  	trials  	 NNS	O
of  	of  	 IN	O
prucalopride  	prucalopride  	 NN	B-NP
were  	were  	 VBD	O
extrapolated  	extrapolated  	 VBN	O
to  	to  	 TO	O
EQ-5D  	EQ-5D  	 CD	B-NP
( 	( 	 -LRB-	O
European  	European  	 NNP	B-NP
Quality  	Quality  	 NNP	I-NP
of  	of  	 IN	I-NP
Life-5  	Life-5  	 NNP	I-NP
Dimensions 	Dimensions 	 NNP	I-NP
)  	)  	 -RRB-	O
data  	data  	 NNS	O
and  	and  	 CC	O
used  	used  	 VBN	O
to  	to  	 TO	O
inform  	inform  	 VB	O
effectiveness  	effectiveness  	 NN	O
in  	in  	 IN	O
an  	an  	 DT	O
economic  	economic  	 JJ	B-NP
model 	model 	 NN	I-NP
.  	.  	 .	O
Response  	Response  	 NN	B-NP
rates  	rates  	 NNS	I-NP
to  	to  	 TO	O
prucalopride  	prucalopride  	 NNS	B-NP
were  	were  	 VBD	O
derived  	derived  	 VBN	O
from  	from  	 IN	O
observed  	observed  	 JJ	O
response  	response  	 NN	B-NP
rates  	rates  	 NNS	I-NP
in  	in  	 IN	O
trials 	trials 	 NNS	O
,  	,  	 ,	O
defined  	defined  	 VBN	O
as  	as  	 IN	O
the  	the  	 DT	O
proportion  	proportion  	 NN	O
of  	of  	 IN	O
patients  	patients  	 NNS	O
achieving  	achieving  	 VBG	O
an  	an  	 DT	O
average  	average  	 NN	O
of  	of  	 IN	O
three  	three  	 CD	O
or  	or  	 CC	O
more  	more  	 RBR	O
spontaneous  	spontaneous  	 JJ	B-NP
complete  	complete  	 JJ	I-NP
bowel  	bowel  	 NN	I-NP
movements  	movements  	 NNS	I-NP
over  	over  	 IN	O
the  	the  	 DT	O
4-  	4-  	 NNP	O
or  	or  	 CC	O
12-week  	12-week  	 CD	O
trial  	trial  	 NN	B-NP
periods 	periods 	 NNS	I-NP
.  	.  	 .	O
Adult  	Adult  	 NNP	B-NP
( 	( 	 -LRB-	O
18-64  	18-64  	 CD	O
years 	years 	 NNS	O
)  	)  	 -RRB-	O
and  	and  	 CC	O
elderly  	elderly  	 JJ	O
( 	( 	 -LRB-	O
≥  	≥  	 CD	O
65  	65  	 CD	O
years 	years 	 NNS	O
)  	)  	 -RRB-	O
patients  	patients  	 NNS	O
were  	were  	 VBD	O
considered  	considered  	 VBN	O
separately  	separately  	 RB	O
in  	in  	 IN	O
the  	the  	 DT	O
model 	model 	 NN	O
.  	.  	 .	O
Cost-effectiveness  	Cost-effectiveness  	 NNP	B-NP
was  	was  	 VBD	O
determined  	determined  	 VBN	O
from  	from  	 IN	O
estimated  	estimated  	 JJ	O
improvements  	improvements  	 NNS	B-NP
in  	in  	 IN	O
EQ-5D  	EQ-5D  	 NNP	B-NP
and  	and  	 CC	O
anticipated  	anticipated  	 JJ	O
response  	response  	 NN	B-NP
rates 	rates 	 NNS	I-NP
,  	,  	 ,	O
adjusted  	adjusted  	 VBN	O
for  	for  	 IN	O
baseline  	baseline  	 JJ	B-NP
severity  	severity  	 NN	I-NP
of  	of  	 IN	I-NP
chronic  	chronic  	 JJ	I-NP
constipation 	constipation 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
ERG  	ERG  	 NNP	O
considered  	considered  	 VBD	O
that  	that  	 IN	O
the  	the  	 DT	O
patients  	patients  	 NNS	O
participating  	participating  	 VBG	O
in  	in  	 IN	O
these  	these  	 DT	O
trials  	trials  	 NNS	O
were  	were  	 VBD	O
not  	not  	 RB	O
representative  	representative  	 JJ	B-NP
of  	of  	 IN	O
those  	those  	 DT	O
in  	in  	 IN	O
the  	the  	 DT	O
licensed  	licensed  	 JJ	O
indication 	indication 	 NN	O
.  	.  	 .	O
They  	They  	 PRP	O
were  	were  	 VBD	O
not  	not  	 RB	O
all  	all  	 DT	O
refractory  	refractory  	 JJ	O
to  	to  	 TO	O
laxatives 	laxatives 	 VB	O
,  	,  	 ,	O
and  	and  	 CC	O
baseline  	baseline  	 CD	B-NP
EQ-5D  	EQ-5D  	 CD	I-NP
scores  	scores  	 NNS	I-NP
showed  	showed  	 VBD	O
a  	a  	 DT	O
large  	large  	 JJ	O
spread  	spread  	 NN	O
in  	in  	 IN	O
quality  	quality  	 NN	O
of  	of  	 IN	O
life 	life 	 NN	O
,  	,  	 ,	O
with  	with  	 IN	O
many  	many  	 JJ	O
patients  	patients  	 NNS	O
experiencing  	experiencing  	 VBG	O
little  	little  	 JJ	O
baseline  	baseline  	 NN	B-NP
dissatisfaction 	dissatisfaction 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
mapping  	mapping  	 NN	O
of  	of  	 IN	O
quality-of-life  	quality-of-life  	 JJ	B-NP
data  	data  	 NNS	I-NP
from  	from  	 IN	O
trials  	trials  	 NNS	O
( 	( 	 -LRB-	O
PAC-QOL  	PAC-QOL  	 NNP	B-NP
and  	and  	 CC	O
PAC-SYM  	PAC-SYM  	 JJ	B-NP
data 	data 	 NNS	I-NP
)  	)  	 -RRB-	O
to  	to  	 TO	O
EQ-5D  	EQ-5D  	 NNP	B-NP
was  	was  	 VBD	O
unclear  	unclear  	 JJ	O
and  	and  	 CC	O
invalidated 	invalidated 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
assumption  	assumption  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
long-term  	long-term  	 JJ	O
effectiveness  	effectiveness  	 NN	O
and  	and  	 CC	O
safety  	safety  	 NN	O
of  	of  	 IN	O
prucalopride  	prucalopride  	 VBG	O
to  	to  	 TO	O
1  	1  	 CD	O
year  	year  	 NN	O
was  	was  	 VBD	O
considered  	considered  	 VBN	O
unjustified 	unjustified 	 NN	O
.  	.  	 .	O
There  	There  	 EX	O
was  	was  	 VBD	O
no  	no  	 DT	O
justification  	justification  	 NN	B-NP
or  	or  	 CC	O
sources  	sources  	 NNS	O
given  	given  	 VBN	O
for  	for  	 IN	O
coefficients  	coefficients  	 VBG	O
used  	used  	 VBN	O
to  	to  	 TO	O
predict  	predict  	 VB	O
effectiveness  	effectiveness  	 NN	O
in  	in  	 IN	O
the  	the  	 DT	O
economic  	economic  	 JJ	B-NP
model 	model 	 NN	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
no  	no  	 DT	O
costs  	costs  	 NNS	O
other  	other  	 JJ	O
than  	than  	 IN	O
the  	the  	 DT	O
cost  	cost  	 NN	O
of  	of  	 IN	O
prucalopride  	prucalopride  	 NN	B-NP
were  	were  	 VBD	O
incorporated  	incorporated  	 VBN	O
into  	into  	 IN	O
the  	the  	 DT	O
model 	model 	 NN	O
.  	.  	 .	O
Owing  	Owing  	 VBG	O
to  	to  	 TO	O
the  	the  	 DT	O
many  	many  	 JJ	O
areas  	areas  	 NNS	O
of  	of  	 IN	O
uncertainty 	uncertainty 	 NN	O
,  	,  	 ,	O
particularly  	particularly  	 RB	O
the  	the  	 DT	O
effectiveness  	effectiveness  	 NN	O
of  	of  	 IN	O
prucalopride  	prucalopride  	 NN	B-NP
in  	in  	 IN	O
the  	the  	 DT	O
licensed  	licensed  	 JJ	O
patient  	patient  	 NN	O
group  	group  	 NN	O
and  	and  	 CC	O
its  	its  	 PRP$	O
long-term  	long-term  	 JJ	O
effectiveness  	effectiveness  	 NN	O
and  	and  	 CC	O
safety 	safety 	 NN	O
,  	,  	 ,	O
it  	it  	 PRP	O
was  	was  	 VBD	O
considered  	considered  	 VBN	O
that  	that  	 IN	O
the  	the  	 DT	O
MS  	MS  	 NNP	B-NP
provided  	provided  	 VBD	O
no  	no  	 DT	O
evidence  	evidence  	 NN	O
for  	for  	 IN	O
whether  	whether  	 IN	O
prucalopride  	prucalopride  	 NN	B-NP
is  	is  	 VBZ	O
effective  	effective  	 JJ	O
or  	or  	 CC	O
not  	not  	 RB	O
in  	in  	 IN	O
women  	women  	 NNS	O
with  	with  	 IN	O
laxative-refractory  	laxative-refractory  	 JJ	B-NP
chronic  	chronic  	 JJ	I-NP
constipation 	constipation 	 NN	I-NP
.  	.  	 .	O
Further  	Further  	 RBR	O
subgroup  	subgroup  	 JJ	B-NP
analysis  	analysis  	 NN	I-NP
of  	of  	 IN	O
the  	the  	 DT	O
actual  	actual  	 JJ	O
patient  	patient  	 NN	O
group  	group  	 NN	O
of  	of  	 IN	O
interest  	interest  	 NN	O
may  	may  	 MD	O
have  	have  	 VB	O
better  	better  	 RBR	O
guided  	guided  	 JJ	O
decision-making 	decision-making 	 NN	O
.  	.  	 .	O
However 	However 	 RB	O
,  	,  	 ,	O
long-term  	long-term  	 JJ	O
efficacy  	efficacy  	 JJ	O
data 	data 	 NNS	O
,  	,  	 ,	O
with  	with  	 IN	O
validated  	validated  	 JJ	O
estimates  	estimates  	 NNS	O
of  	of  	 IN	O
quality  	quality  	 NN	O
of  	of  	 IN	O
life  	life  	 NN	O
incorporated  	incorporated  	 VBN	O
in  	in  	 IN	O
a  	a  	 DT	O
well-founded  	well-founded  	 JJ	O
model 	model 	 NN	O
,  	,  	 ,	O
would  	would  	 MD	O
be  	be  	 VB	O
important  	important  	 JJ	O
for  	for  	 IN	O
an  	an  	 DT	O
evidence-based  	evidence-based  	 JJ	O
judgement  	judgement  	 NN	O
to  	to  	 TO	O
be  	be  	 VB	O
made 	made 	 VBN	O
.  	.  	 .	O
